Clinical Trials Browser

INDUSTRY × AZD 6244 × Gastrointestinal × Clear all

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT01949870 2016-05-13

Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

Phase 1 Terminated

6 enrolled 6 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT00372944 2014-08-13

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00514761 2014-08-13

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms